Cargando…

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

Rheumatoid arthritis is a heterogeneous disease with respect to clinical manifestations, serologic abnormalities, joint damage and functional impairment. Predicting outcome in a reliable way to allow for strategic therapeutic decision-making as well as for prediction of the response to the various t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, Aletaha, Daniel, Grisar, Johannes, Redlich, Kurt, Steiner, Günter, Wagner, Oswald
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483438/ https://www.ncbi.nlm.nih.gov/pubmed/18557991 http://dx.doi.org/10.1186/ar2418

Ejemplares similares

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
por: Nagy, György, et al.
Publicado: (2015)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?
por: Buttgereit, Frank, et al.
Publicado: (2015)

Post-streptococcal reactive arthritis: where are we now
por: Pathak, Himanshu, et al.
Publicado: (2016)

Addressing Psychiatry Workforce Needs: Where Are We Now?
por: Aggarwal, Rashi, et al.
Publicado: (2022)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis
por: Studenic, Paul, et al.
Publicado: (2021)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Ebola virus convalescent blood products: Where we are now and where we may need to go
por: Burnouf, Thierry, et al.
Publicado: (2014)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Expanded Network of Inflammatory Markers of Atherogenesis: Where Are We Now?
por: Abbasi, Seyed Hesameddin, et al.
Publicado: (2010)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

The impact of ICCPR's Global Audit of Cardiac Rehabilitation: where are we now and where do we need to go?
por: Turk-Adawi, Karam, et al.
Publicado: (2023)

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?
por: Halilova, Karina I., et al.
Publicado: (2012)

The role of osteoprotegerin in arthritis
por: Schett, Georg, et al.
Publicado: (2003)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal workstations: Where are we now?
por: Willers, Ian Malcolm
Publicado: (1982)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Intracranial Atherosclerosis: Where Are We Now?
por: Kim, Jong S.
Publicado: (2017)

Mindfulness in psychiatry – where are we now?
por: Groves, Paramabandhu
Publicado: (2016)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

Microbiota and Obesity: Where Are We Now?
por: Ballini, Andrea, et al.
Publicado: (2020)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qq3n8elirdcds3n5d6tm1fjv6